164 related articles for article (PubMed ID: 12957371)
1. Compromised reactive microgliosis in MPTP-lesioned IL-6 KO mice.
Cardenas H; Bolin LM
Brain Res; 2003 Sep; 985(1):89-97. PubMed ID: 12957371
[TBL] [Abstract][Full Text] [Related]
2. Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice.
Bolin LM; Strycharska-Orczyk I; Murray R; Langston JW; Di Monte D
J Neurochem; 2002 Oct; 83(1):167-75. PubMed ID: 12358740
[TBL] [Abstract][Full Text] [Related]
3. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
[TBL] [Abstract][Full Text] [Related]
4. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.
Wu DC; Jackson-Lewis V; Vila M; Tieu K; Teismann P; Vadseth C; Choi DK; Ischiropoulos H; Przedborski S
J Neurosci; 2002 Mar; 22(5):1763-71. PubMed ID: 11880505
[TBL] [Abstract][Full Text] [Related]
5. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
[TBL] [Abstract][Full Text] [Related]
6. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure.
Barcia C; Sánchez Bahillo A; Fernández-Villalba E; Bautista V; Poza Y Poza M; Fernández-Barreiro A; Hirsch EC; Herrero MT
Glia; 2004 May; 46(4):402-9. PubMed ID: 15095370
[TBL] [Abstract][Full Text] [Related]
7. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
Kim S; Moon M; Park S
J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
[TBL] [Abstract][Full Text] [Related]
8. Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.
Hu X; Zhang D; Pang H; Caudle WM; Li Y; Gao H; Liu Y; Qian L; Wilson B; Di Monte DA; Ali SF; Zhang J; Block ML; Hong JS
J Immunol; 2008 Nov; 181(10):7194-204. PubMed ID: 18981141
[TBL] [Abstract][Full Text] [Related]
9. Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
L'Episcopo F; Tirolo C; Testa N; Caniglia S; Morale MC; Cossetti C; D'Adamo P; Zardini E; Andreoni L; Ihekwaba AE; Serra PA; Franciotta D; Martino G; Pluchino S; Marchetti B
Neurobiol Dis; 2011 Feb; 41(2):508-27. PubMed ID: 21056667
[TBL] [Abstract][Full Text] [Related]
10. Neuroinflammation in Parkinson's patients and MPTP-treated mice is not restricted to the nigrostriatal system: microgliosis and differential expression of interleukin-1 receptors in the olfactory bulb.
Vroon A; Drukarch B; Bol JG; Cras P; Brevé JJ; Allan SM; Relton JK; Hoogland PV; Van Dam AM
Exp Gerontol; 2007 Aug; 42(8):762-71. PubMed ID: 17592750
[TBL] [Abstract][Full Text] [Related]
11. Metalloproteinase-9 contributes to inflammatory glia activation and nigro-striatal pathway degeneration in both mouse and monkey models of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism.
Annese V; Herrero MT; Di Pentima M; Gomez A; Lombardi L; Ros CM; De Pablos V; Fernandez-Villalba E; De Stefano ME
Brain Struct Funct; 2015 Mar; 220(2):703-27. PubMed ID: 24558048
[TBL] [Abstract][Full Text] [Related]
12. Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo.
Choi SH; Joe EH; Kim SU; Jin BK
J Neurosci; 2003 Jul; 23(13):5877-86. PubMed ID: 12843292
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.
Sugama S; Wirz SA; Barr AM; Conti B; Bartfai T; Shibasaki T
Neuroscience; 2004; 128(2):451-8. PubMed ID: 15350655
[TBL] [Abstract][Full Text] [Related]
14. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo.
Dehmer T; Lindenau J; Haid S; Dichgans J; Schulz JB
J Neurochem; 2000 May; 74(5):2213-6. PubMed ID: 10800968
[TBL] [Abstract][Full Text] [Related]
15. Exacerbation of dopaminergic terminal damage in a mouse model of Parkinson's disease by the G-protein-coupled receptor protease-activated receptor 1.
Hamill CE; Caudle WM; Richardson JR; Yuan H; Pennell KD; Greene JG; Miller GW; Traynelis SF
Mol Pharmacol; 2007 Sep; 72(3):653-64. PubMed ID: 17596374
[TBL] [Abstract][Full Text] [Related]
16. Tanshinone IIA prevents the loss of nigrostriatal dopaminergic neurons by inhibiting NADPH oxidase and iNOS in the MPTP model of Parkinson's disease.
Ren B; Zhang YX; Zhou HX; Sun FW; Zhang ZF; Wei Z; Zhang CY; Si DW
J Neurol Sci; 2015 Jan; 348(1-2):142-52. PubMed ID: 25491263
[TBL] [Abstract][Full Text] [Related]
17. Bee venom reduces neuroinflammation in the MPTP-induced model of Parkinson's disease.
Kim JI; Yang EJ; Lee MS; Kim YS; Huh Y; Cho IH; Kang S; Koh HK
Int J Neurosci; 2011 Apr; 121(4):209-17. PubMed ID: 21265705
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment.
Knyihár-Csillik E; Csillik B; Pákáski M; Krisztin-Péva B; Dobó E; Okuno E; Vécsei L
Neuroscience; 2004; 126(4):899-914. PubMed ID: 15207325
[TBL] [Abstract][Full Text] [Related]
19. Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Furuya T; Hayakawa H; Yamada M; Yoshimi K; Hisahara S; Miura M; Mizuno Y; Mochizuki H
J Neurosci; 2004 Feb; 24(8):1865-72. PubMed ID: 14985426
[TBL] [Abstract][Full Text] [Related]
20. Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.
Heng Y; Zhang QS; Mu Z; Hu JF; Yuan YH; Chen NH
Toxicol Lett; 2016 Jan; 243():7-21. PubMed ID: 26723869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
